

## **Curriculum vitae including publication list**

Name: Frank Griesinger

Adress: Dept. Hematology/Oncology, University Dept. Internal Medicine- Oncology, Pius-Hospital Oldenburg, Georgstrasse 12, D - 26121 Oldenburg

Academic degree: Prof. Dr. med., M.D., Ph.D.

Date of birth: 05.04.1960

Place of birth: Ulm/Donau, Germany

Nationality: German

Phone.: + 49 (441) 229 1610, 1611 (Sekretariate), + 49 (441) 229 -1126 Study sekretariate,

Fax:+ 49 (441) 229 1607

Email: [frank.griesinger@pius-hospital.de](mailto:frank.griesinger@pius-hospital.de), [frank.griesinger@uni-oldenburg.de](mailto:frank.griesinger@uni-oldenburg.de)

## **Work**

Since 2013	W3 Professor for Internal Medicine-Oncology
Since 2006	Director Dept. Heme-Oncology Pius-Hospital, Oldenburg
1998 -2006:	Attending/Assistant Professor Div. Hematology and Oncology, Georg-August-University, Göttingen, Responsible for study sekretariate, specialized hematology diagnostics
1992-1998:	Resident Div. Hematology/Oncology, Georg-August-University Göttingen
1990-1992:	Resident Div. Hematology/Oncology/Hemostaseology, Westf. Wilhelms-Universität, Münster,
1987-1989:	Postdoctoral Fellowship, Immunology, Hematology and cell biology at Dept. of Laboratory Medicine and Pathology, University of Minnesota, USA
1986-1987:	Resident Div. Hematology and Oncology, Johann-Wolfgang-Goethe-University, Frankfurt/Main,

## **Specialization**

Since 2010	Coordinator Cancer Center Oldenburg, Pius-Hospital
2003	ESMO Certificate
2001	Board certification for Hematology and Oncology
5/99	PhD/ Habilitation Internal Medicine
1998	Board certification for Internal Medicine
1992-2006:	Molecular biology Div. Hem/Onc, University Göttingen
1990-1992	Molecular biology, Dept. Heme/Onc/Hemostaseology, Westf. Wilhelms-Universität, Münster
1989:	ECFMG Certificate

1987-1989: Postdoctoral Fellowship, Immunology, Hematology and cell biology at Dept.of Laboratory Medicine and Pathology, University of Minnesota, USA,  
 1983-1987: M.D.-Thesis, Div. Pharmacology, J-W-Goethe-University

**Honors and councilorships:**

1993 Poster-Prize DGHO  
 1998 Theodor Frerichs-Prize German Society of Internal Medicine  
 2003 Poster-Prize WCLC, Vancouver, Ca.  
 2013: DGHO Poster Prize Berlin  
 2016 Prize of the AIO for the most innovative study (CRISP)  
 Since 1987: American Society of Hematology  
 Since 1992: American Society of Clinical Oncology  
 Since 1986: Deutsche Gesellschaft für Innere Medizin (German Society of Internal Medicine)  
 Since 1995: Deutsche Krebsgesellschaft (German Cancer Society)  
 Since 1995: Working Group Medical Oncology, thoracic tumor group, deputy head from 11/2017-11/2019, head elect starting 11/2019 to 11/2021  
 Since 2009: IASLC (International Association for the Study of Lung Cancer)  
 Since 1987: German Society of Hematology and Oncology  
 Since 2009: DGHO-delegate for the certification commission for lung cancer centers  
 Since 2009: DGHO- delegate of the S3 guidelines for lung cancer  
 Since 2015: DGHO author for the Oncopectia guidelines for lung cancer  
 Since 2015: Member of the Working group CNS tumors, DGHO  
 Since 2021: Netzwerkzentrum im nationalen Netzwerk Genomische Medizin (nNGM)  
 Since 2015 NOWEL Lung network (now renamed Lungenkrebsmedizin-Oldenburg)  
 Since 2015: Chair of the medical ethics committee of the University of Oldenburg  
 Since 2015: Speaker CRISP, prospective Registry for NSCLC and SCLC


**Teaching:**

Since 2011: Coordinator of the oncology teaching module for medical students at the University of Oldenburg  
 Since 2011: GCP courses (AMG)  
 Since 2019: Teacher for the medical physics students  
 Since 2020: Teacher for the studies in molecular biomedicine (Tumor biology)  
 Since 2018 Teacher for the Hanse Institute (Nursing students)

## **Guidelines in lung cancer therapy:**

1. **Frank Griesinger**, Gudrun Absenger, Wilfried Eberhardt, Martin Früh, Oliver Gautschi, Wolfgang Hilbe, Hans Hoffmann, Rudolf Maria Huber, Sonja Loges, Christoph Pöttgen, Ron Pritzkeleit, Martin Reck, Niels Reinmuth, Martin Sebastian, Cornelius Waller, Jürgen Wolf, Martin Wolf, Bernhard Wörmann: Lungenkarzinom, nicht-kleinzellig (NSCLC) 2021  
<https://www.onkopedia.com/de/onkopedia/guidelines/lungenkarzinom-nicht-kleinzellig-nsclc/@@guideline/html/index.html>
2. Martin Wolf, Wilfried Eberhardt, Martin Früh, Oliver Gautschi, **Frank Griesinger**, Wolfgang Hilbe, Hans Hoffmann, Rudolf Maria Huber, Sonja Loges, Robert Pirker, Christoph Pöttgen, Ron Pritzkeleit, Martin Reck, Niels Reinmuth, Martin Sebastian, Dieter Ukena, Cornelius Waller, Jürgen Wolf, Bernhard Wörmann: Lungenkarzinom, kleinzellig (SCLC) 2019 .  
<https://www.onkopedia.com/de/onkopedia/guidelines/lungenkarzinom-kleinzellig-sclc/@@guideline/html/index.html>
3. R. Büttner, J. Wolf, The national Network Genomic Medicine (nNGM): Model for innovative diagnostics and therapy of lung cancer within a public healthcare system
4. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF), Deutschen Krebsgesellschaft e.V. (DKG) und Deutschen Krebshilfe (DKH): S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms 2018.  
[https://www.awmf.org/uploads/tx\\_szleitlinien/020-007OL\\_1\\_S3\\_Lungenkarzinom\\_2018-03.pdf](https://www.awmf.org/uploads/tx_szleitlinien/020-007OL_1_S3_Lungenkarzinom_2018-03.pdf)

07.11.2021



## **„Peer-reviewed” publications incl. authors:**

1. Ramdani HO, Falk M, Heukamp LC, Schatz S, Tiemann M, Wessler C, Diehl L, Schuurung E, Groen HJM, **Griesinger F**. [Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors](#). Pathol Res Pract. 2021 Oct 12;227:153651. doi: 10.1016/j.prp.2021.153651.
2. Novello S, Torri V, Grohe C, Kurz S, Serke M, Wehler T, Meyer A, Ladage D, Geissler M, Colantonio I, Cauchi C, Stoelben E, Ceribelli A, Kropf-Sanchen C, Valmadre G, Borra G, Schena M, Morabito A, Santo A, Gregorc V, Chiari R, Reck M, Schmid-Bindert G,

- Folprecht G, **Griesinger F**, Follador A, Pedrazzoli P, Bearz A, Caffo O, Dickgreber NJ, Irtelli L, Wiest G, Monica V, Porcu L, Manegold C, Scagliotti GV. [International Tailored Chemotherapy Adjuvant \(ITACA\) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIa non-small-cell lung cancer.](#) *Ann Oncol.* 2021 Oct 5:S0923-7534(21)04496-3. doi: 10.1016/j.annonc.2021.09.017.
3. Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, Molinier O, Nackaerts K, Insa Mollá A, Gervais R, López Vivanco G, Madelaine J, Mazieres J, Faehling M, **Griesinger F**, Majem M, González Larriba JL, Provencio Pulla M, Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel RA, Le Pechoux C, De Ruyscher D; ETOP/IFCT 4-12 STIMULI Collaborators. [Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.](#) *Ann Oncol.* 2021 Sep 23:S0923-7534(21)04490-2. doi: 10.1016/j.annonc.2021.09.011.
  4. Shah R, Girard N, Nagar SP, **Griesinger F**, Roeper J, Davis KL, Karimi P, Sawyer W, Yu N, Taylor A, Feliciano J. [European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review.](#) *Drugs Real World Outcomes.* 2021 Sep 17. doi: 10.1007/s40801-021-00261-8.
  5. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, **Griesinger F**, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S. [Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.](#) *J Thorac Oncol.* 2021 Sep 16:S1556-0864(21)02398-4. doi: 10.1016/j.jtho.2021.07.035.
  6. **Griesinger F**, Thomas M. [When to Test in Biomarker-stratified Therapy of Non-small Cell Lung Cancer - Biomarker-stratified Therapy of Non-small Cell Lung Cancer: When and What to Test?\].](#) *Pneumologie.* 2021 Sep;75(9):641-643. doi: 10.1055/a-1486-9057. Epub 2021 Sep 15
  7. Lubasch JS, Voigt-Barbarowicz M, Lippke S, De Wilde RL, **Griesinger F**, Lazovic D, Ocampo Villegas PC, Roeper J, Salzmann D, Seeber GH, Torres-de-la-Roche LA, Weyhe D, Ansmann L, Brütt AL. [Improving professional health literacy in hospitals: study protocol of a participatory codesign and implementation study.](#) *BMJ Open.* 2021 Aug 16;11(8):e045835. doi: 10.1136/bmjopen-2020-045835. PMID: 34400444
  8. Jóri B, Schatz S, Kaller L, Kah B, Roeper J, Ramdani HO, Diehl L, Hoffknecht P, Grohé C, **Griesinger F**, Tiemann M, Heukamp LC, Falk M. Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy. *Cancers (Basel).* 2021 Jun 8;13(12):2861. doi: 10.3390/cancers13122861
  9. Popat S, Brustugun OT, Cadranel J, Felip E, Garassino MC, **Griesinger F**, Helland Å, Hochmair M, Pérol M, Bent-Enkhil N, Kruhl C, Novello S. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. *Lung Cancer.* 2021 Jul;157:9-16. doi: 10.1016/j.lungcan.2021.05.017. Epub 2021 May 24.
  10. Wiesweg M, Preuß C, Roeper J, Metzenmacher M, Eberhardt W, Stropiep U, Wedeken K, Reis H, Herold T, Darwiche K, Aigner C, Stuschke M, Schildhaus HU, Schmid KW, Falk M, Heukamp L, Tiemann M, **Griesinger F**, Schuler M. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. *Eur J Cancer.* 2021 May;149:211-221. doi: 10.1016/j.ejca.2021.02.036. Epub 2021 Apr 16.

11. Harbeck N, Schneeweiss A, Thuss-Patience P, Miller K, Garbe C, **Griesinger F**, Eberhardt WEE, Klussmann JP, Wollenberg B, Grimm MO, Zander T, Lüftner D. Neoadjuvant and adjuvant end-points in health technology assessment in oncology. *Eur J Cancer*. 2021 Apr;147:40-50. doi: 10.1016/j.ejca.2021.01.006. Epub 2021 Feb 19.
12. Sebastian M, Eberhardt WEE, Hoffknecht P, Metzenmacher M, Wehler T, Kokowski K, Alt J, Schütte W, Büttner R, Heukamp LC, Stenzinger A, Jänicke M, Fleitz A, Zacharias S, Dille S, Hipper A, Sandberg M, Weichert W, Groschek M, von der Heyde E, Rauh J, Dechow T, Thomas M, **Griesinger F**; CRISP Registry Group. KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). *Lung Cancer*. 2021 Apr;154:51-61. doi: 10.1016/j.lungcan.2021.02.005. Epub 2021 Feb 13.
13. Metzenmacher M, Kopp HG, **Griesinger F**, Reinmuth N, Sebastian M, Serke M, Waller CF, Thomas M, Eggert J, Schmid-Bindert G, Hoiczky M, Christoph DC, Kimmich M, Deuß B, Seifert S, Held S, Schuler M, Herold T, Breitenbuecher F, Eberhardt WEE. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. *Ther Adv Med Oncol*. 2021 Mar 9;13:1758835921996506. doi: 10.1177/1758835921996506. eCollection 2021.
14. Brückl WM, Reck M, **Griesinger F**, Schäfer H, Kortsik C, Gaska T, Rawluk J, Krüger S, Kokowski K, Budweiser S, Ficker JH, Hoffmann C, Schüler A, Laack E. Afatinib as first-line treatment in patients with *EGFR*-mutated non-small cell lung cancer in routine clinical practice. *Ther Adv Med Oncol*. 2021 May 6;13:17588359211012361. doi: 10.1177/17588359211012361. eCollection 2021.
15. Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, Alt J, Gütz S, Christoph DC, Laack E, Faehling M, Fischer R, Fenchel K, Haen S, Heukamp L, Schulz C, **Griesinger F**. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. *Ther Adv Med Oncol*. 2021 Feb 9;13:1758835920980558. doi: 10.1177/1758835920980558. eCollection 2021.
16. Roeper J, Kurz S, Grohé C, **Griesinger F**. Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC. *Future Oncol*. 2021 Feb;17(4):471-486. doi: 10.2217/fon-2020-0854. Epub 2020 Oct 23.
17. Christopoulos P, Kirchner M, Roeper J, Saalfeld F, Janning M, Bozorgmehr F, Magios N, Kazdal D, Volckmar AL, Brückner LM, Bochtler T, Kriegsmann M, Endris V, Penzel R, Kriegsmann K, Eichhorn M, Herth FJF, Heussel CP, El Shafie RA, Schneider MA, Muley T, Meister M, Faehling M, Fischer JR, Heukamp L, Schirmacher P, Bischoff H, Wermke M, Loges S, **Griesinger F**, Stenzinger A, Thomas M. Risk stratification of EGFR<sup>+</sup> lung cancer diagnosed with panel-based next-generation sequencing. *Lung Cancer*. 2020 Oct;148:105-112. doi: 10.1016/j.lungcan.2020.08.007. Epub 2020 Aug 22.
18. Hardtstock F, Myers D, Li T, Cizova D, Maywald U, Wilke T, **Griesinger F**. Real-world treatment and survival of patients with advanced non-small cell lung cancer: a German retrospective data analysis. *BMC Cancer*. 2020 Mar 30;20(1):260. doi: 10.1186/s12885-020-06738-z.
19. **Griesinger F**, Thomas M [When to test in biomarker-stratified therapy of non-small cell lung cancer - Biomarker-stratified therapy of Non-small cell lung cancer: when and what to test?]. *Dtsch Med Wochenschr*. 2021 Apr;146(8):559-561. doi: 10.1055/a-1383-5231. Epub 2021 Apr 14
20. **Griesinger F**, Eberhardt W, Nusch A, Reiser M, Zahn MO, Maintz C, Bernhardt C, Losem C, Stenzinger A, Heukamp LC, Büttner R, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Heilmann M, Sadjadian P, Gleiber W, Grah C, Waller CF, Reck M, Rittmeyer A, Christopoulos P, Sebastian M,

- Thomas M; CRISP Registry Group. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). *Lung Cancer*. 2021 Feb;152:174-184. doi: 10.1016/j.lungcan.2020.10.012. Epub 2020 Nov 2.
21. Stenzinger A, van Tilburg CM, Tabatabai G, Länger F, Graf N, **Griesinger F**, Heukamp LC, Hummel M, Klingebiel T, Hettmer S, Vokuhl C, Merkelbach-Bruse S, Overkamp F, Reichardt P, Scheer M, Weichert W, Westphalen CB, Bokemeyer C, Ivanyi P, Loges S, Schirmacher P, Wörmann B, Bielack S, Seufferlein TTW. [Diagnosis and therapy of tumors with NTRK gene fusion]. *Pathologe*. 2021 Feb;42(1):103-115. doi: 10.1007/s00292-020-00864-y
  22. Schatz S, Falk M, Jóri B, Ramdani HO, Schmidt S, Willing EM, Menon R, Groen HJM, Diehl L, Kröger M, Wessler C, **Griesinger F**, Hoffknecht P, Tiemann M, Heukamp LC Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer. *Cancers (Basel)*. 2020 Jun 24;12(6):1685. doi: 10.3390/cancers12061685
  23. Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, **Griesinger F**, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, John A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with *MET* Exon 14 Skipping Mutations. *N Engl J Med*. 2020 May 29. doi: 10.1056/NEJMoa2004407.
  24. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, **Griesinger F**, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. *J Clin Oncol*. 2020 Nov 1;38(31):3592-3603. doi: 10.1200/JCO.20.00505. Epub 2020 Aug 11
  25. Gridelli C, Ciuleanu T, Domine M, Szczesna A, Bover I, Cobo M, Kentepozidis N, Zarogoulidis K, Kalofonos C, Kazarnowisz A, Korozan M, de Las Penas R, Majem M, Chella A, **Griesinger F**, Bournakis E, Sadjadian P, Kotsakis A, Chinet T, Syrigos KN, Correale P, Gallou C, Jamet JM, Vetsika EK, Kosmatopoulos K, Georgoulis V; Vx-001-201 trial team. Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial. *Br J Cancer*. 2020 Mar 25. doi: 10.1038/s41416-020-0785-y.
  26. Roeper J, Falk M, Chalaris-Rißmann A, Lueers AC, Ramdani H, Wedeken K, Stropiep U, Diehl L, Tiemann M, Heukamp LC, Otto-Sobotka F, **Griesinger F**. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC. *Oncotarget*. 2020 Jan 21;11(3):250-264. doi: 10.18632/oncotarget.27430. eCollection 2020 Jan 21
  27. **Griesinger F**, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM.. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. *Lung Cancer*. 2019 Sep;135:196-204. doi: 10.1016/j.lungcan.2019.07.010. Epub 2019 Jul 13
  28. Krefting F, Basara N, Schütte W, Späth-Schwalbe E, Alt J, Thiel S, Kimmich M, Fischer JR, Kurz S, **Griesinger F**, Christoph DC. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer *Oncol Res Treat*. 2019;42(5):243-255. doi: 10.1159/000499321. Epub 2019 Apr 17.

29. Ekman S, **Griesinger F**, Baas P, Chao D, Chouaid C, O'Donnell JC, Penrod JR, Daumont M, Lacoïn L, McKenney A, Khovratovich M, Munro RE, Durand-Zaleski I, Johnsen SP. I-O Optimise: a novel multinational real-world research platform in thoracic malignancies. *Future Oncol.* 2019 May;15(14):1551-1563. doi: 10.2217/fon-2019-0025. Epub 2019 Mar 11.
30. Wuerstlein R, Kates R, Gluz O, Grischke EM, Schem C, Thill M, Hasmueller S, Köhler A, Otremba B, **Griesinger F**, Schindlbeck C, Trojan A, Otto F, Knauer M, Pusch R, Harbeck N; WSG-PRIME investigators in Germany, Austria, Switzerland. Strong impact of MammaPrint and Blueprint on treatment decisions in luminal early breast cancer: results of the WSG-PRIME study. *Breast Cancer Res Treat.* 2019 Jun;175(2):389-399. doi: 10.1007/s10549-018-05075-x. Epub 2019 Feb 22.
31. Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, **Griesinger F**, Kallen KJ, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong HS, Koch SD, Gnad-Vogt U, Zippelius A. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. *J Immunother Cancer.* 2019 Feb 8;7(1):38. doi: 10.1186/s40425-019-0520-5
32. Halmos B, Tan EH, Soo RA, Cadranel J, Lee MK, Foucher P, Hsia TC, Hochmair M, **Griesinger F**, Hida T, Kim E, Melosky B, Märten A, Carcereny E. Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). *Lung Cancer.* 2019 Jan;127:103-111. doi: 10.1016/j.lungcan.2018.10.028. Epub 2018 Nov 2.
33. Michels S, Heydt C, van Veggel B, Deschler-Baier B, Pardo N, Monkhorst K, Rüsseler V, Stratmann J, **Griesinger F**, Steinhauser S, Kostenko A, Diebold J, Fassunke J, Fischer R, Engel-Riedel W, Gautschi O, Geissinger E, Haneder S, Ihle MA, Kopp HG, de Langen AJ, Martinez-Marti A, Nogova L, Persigehl T, Plenker D, Poesken M, Rodermann E, Rosenwald A, Scheel AH, Scheffler M, Spengler W, Seggewiss-Bernhardt R, Brägelmann J, Sebastian M, Vrugt B, Hellmich M, Sos ML, Heukamp LC, Felip E, Merkelbach-Bruse S, Smit EF, Büttner R, Wolf J. Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. *JCO Precis Oncol.* 2019 Mar 27;3:PO.18.00210. doi: 10.1200/PO.18.00210. eCollection 2019.
34. Roper J, **Griesinger F**. Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy? *Curr Opin Oncol.* 2019 Jan;31(1):1-7. doi: 10.1097/CCO.0000000000000495.
35. **Griesinger F**, Roper J, Pöttgen C, Willborn KC, Eberhardt WEE. Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms. *Oncotarget.* 2018 Oct 12;9(80):35181-35194. doi: 10.18632/oncotarget.26073. eCollection 2018 Oct 12. Review.
36. **Griesinger F**, Radke S, Lüers A, Deschler-Baier B, Kimmich M, Sebastian M, Schulz C, Brugger W, Wiewrodt R, Pirker R, Früh M, Gautschi O, Wolf J. Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example. *Pneumologie.* 2018 Nov;72(11):774-781. doi: 10.1055/a-0647-9835. Epub 2018 Nov 8. German.
37. Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, **Griesinger F**, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. *N Engl J Med.* 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25.
38. Stratmann JA, Michels S, Hornetz S, Christoph DC, Sackmann S, Spengler W, Bischoff H, Schäfer M, Alt J, Müller A, Laack E, Kimmich M, Griesinger F, Sebastian M. Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small

- cell lung cancer. *J Cancer Res Clin Oncol*. 2018 Dec;144(12):2457-2463. doi: 10.1007/s00432-018-2754-x. Epub 2018 Sep 22.
39. Gridelli C, de Castro Carpeno J, Dingemans AC, **Griesinger F**, Grossi F, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial. *JAMA Oncol*. 2018 Aug 30:e183486. doi: 10.1001/jamaoncol.2018.3486. [Epub ahead of print]
  40. Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, **Griesinger F**, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. *Ann Oncol*. 2018 Jun 1;29(6):1409-1416. doi: 10.1093/annonc/mdy121
  41. Plenker D, Bertrand M, de Langen AJ, Riedel R, Lorenz C, Scheel AH, Müller J, Brägelmann J, Daßler-Plenker J, Kobe C, Persigehl T, Kluge A, Wurdinger T, Schellen P, Hartmann G, Zacherle T, Menon R, Thunnissen E, Büttner R, **Griesinger F**, Wolf J, Heukamp L, Sos ML, Heuckmann JM. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. *Clin Cancer Res*. 2018 Mar 15;24(6):1337-1343. doi: 10.1158/1078-0432.CCR-17-3001. Epub 2017 Dec 28.
  42. **Griesinger F**. Current Aspects of Diagnosis and Treatment of Lung Cancer]. *Dtsch Med Wochenschr*. 2017 Dec;142(24):1808-1812. doi: 10.1055/s-0043-112779. Epub 2017 Dec 5. German.
  43. Lakis S, Heukamp LC, **Griesinger F**. Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non-Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy. *J Thorac Oncol*. 2017 Nov;12(11):e186-e188. doi: 10.1016/j.jtho.2017.07.018.
  44. Müller JN, Falk M, Talwar J, Neemann N, Mariotti E, Bertrand M, Lakis S, Menon R, Gloeckner C, Tiemann M, Heukamp L, Thomas RK, **Griesinger F**, Heuckmann JM. Concordance between comprehensive cancer genome profiling in plasma and tumor specimens. *J Thorac Oncol*. 2017 Oct;12(10):1503-1511. doi: 10.1016/j.jtho.2017.07.014. Epub 2017 Jul 24
  45. Lakis S, Heukamp LC, **Griesinger F**. Detection of discrepant driver mutations in a patient with two synchronous primary non-small cell lung cancers (NSCLC) with liquid biopsy *J Thorac Oncol*. 2017 Nov;12(11):e186-e188. doi: 10.1016/j.jtho.2017.07.018.
  46. Herrlinger U, Schäfer N, Fimmers R, **Griesinger F**, Rauch M, Kirchen H, Roth P, Glas M, Bamberg M, Martus P, Thiel E, Korfel A, Weller M. Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. *J Cancer Res Clin Oncol*. 2017 Apr 22. doi: 10.1007/s00432-017-2423-5. [Epub ahead of print]
  47. von Laffert M, Schirmacher P, Warth A, Weichert W, Büttner R, Huber RM, Wolf J, **Griesinger F**, Dietel M, Grohé C. ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.). *Lung Cancer*. 2017 Jan;103:1-5. doi: 10.1016/j.lungcan.2016.11.008.
  48. Schuette W, Dietel M, Thomas M, Eberhardt W, **Griesinger F**, Zirrgiebel U, Radke S, Schirmacher P. [Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy]. *Pneumologie*. 2016 Aug;70(8):514-21. doi: 10.1055/s-0042-109749. Epub 2016 Aug 11. German.
  49. Heukamp L, Menon R, Müller J, Lakis S, Netchaeva M, **Griesinger F**, Eberhardt W, Heuckmann JM. 65P NEOLiquid: Detection of KIF5B-RET fusions in liquid biopsy samples. *J Thorac Oncol*. 2016 Apr;11(4 Suppl):S82-3. doi: 10.1016/S1556-0864(16)30178-2. Epub 2016 Apr 15. No abstract available.
  50. Menon R, Müller J, Schneider P, Lakis S, Thress K, Wolf J, Heukamp L, Heuckmann JM, **Griesinger F**. A Novel EGFR<sup>C797</sup> Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay. *J Thorac Oncol*. 2016 Apr 13. pii: S1556-0864(16)30090-9. doi: 10.1016/j.jtho.2016.04.005. [Epub ahead of print] No abstract available.
  51. de Marinis F, Bria E, Ciardiello F, Crinò L, Douillard JY, **Griesinger F**, Lambrechts D, Perol M, Ramalingam SS, Smit EF, Gridelli C. International Experts Panel Meeting of the Italian Association of



- Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes. *J Thorac Oncol.* 2016 Jul;11(7):1153-69. doi: 10.1016/j.jtho.2016.03.015. Epub 2016 Apr 5.
52. von Laffert M, Schirmacher P, Warth A, Weichert W, Büttner R, Huber RM, Wolf J, **Griesinger F**, Dietel M, Grohé C. [Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC : Immunohistochemistry and/or FISH?]. *Pathologe.* 2016 Mar;37(2):187-92. doi: 10.1007/s00292-016-0152-1. German. No abstract available.
  53. von Laffert M, Schirmacher P, Warth A, Weichert W, Büttner R, Huber RM, Wolf J, **Griesinger F**, Dietel M, Grohé Ch. [ALK-Diagnostics in NSCLC - Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)]. *Pneumologie.* 2016 Apr;70(4):277-81. doi: 10.1055/s-0042-102626. Epub 2016 Mar 16. German.
  54. Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt WE, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, **Griesinger F**, Thomas M; TREAT investigators. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). *J Thorac Oncol.* 2016 Jan;11(1):85-93. doi: 10.1016/j.jtho.2015.09.014.
  55. Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, **Griesinger F**, Scheffler M; Afatinib Compassionate Use Consortium (ACUC). Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. *Oncologist.* 2015 Oct;20(10):1167-74. doi: 10.1634/theoncologist.2015-0073. Epub 2015 Sep 9.
  56. Korfel A, Thiel E, Martus P, Möhle R, **Griesinger F**, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. *Neurology.* 2015 Mar 24;84(12):1242-8. doi: 10.1212/WNL.0000000000001395. Epub 2015 Feb 25.
  57. Sebastian M, Niederle N, Thomas M, Reck M, Schmittel A, Fischer B, Overbeck T, Gröschel A, Deppermann M, Pirker R, Huber RM, Eberhardt W, **Griesinger F**. [Molecular genetic tests in advanced non-small cell lung cancer: practical relevance]. *Dtsch Med Wochenschr.* 2014 Oct;139(41):2096-100. doi: 10.1055/s-0034-1387294. Epub 2014 Sep 30. Review. German. No abstract available.
  58. Kreher S, Strehlow F, Martus P, Roth P, Hertenstein B, Röth A, Birnbaum T, **Griesinger F**, Rauch M, Kanz L, Thiel E, Weller M, Korfel A. Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. *Ann Hematol.* 2015 Mar;94(3):409-14. doi: 10.1007/s00277-014-2212-z. Epub 2014 Sep 13.
  59. Hohloch K, Bertram N, Trümper L, Beissbarth T, **Griesinger F**. Superior vena cava syndrome caused by a malignant tumor: a retrospective single-center analysis of 124 cases. *J Cancer Res Clin Oncol.* 2014 Dec;140(12):2129-34. doi: 10.1007/s00432-014-1764-6. Epub 2014 Jul
  60. Kreuter M, Vansteenkiste J, Herth FJ, Fischer JR, Eberhardt W, Zuna I, Reinmuth N, **Griesinger F**, Thomas M; TREAT investigators. Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancer. *Respiration.* 2014;87(3):204-10. doi: 10.1159/000355361. Epub 2013 Oct 30. Impact Faktor/Wichtungsfaktor per Kategorie: 2,924/2,570
  61. **Griesinger F**, Huber RM, Thomas M, Wolf M. Structures and ways of decision making in thoracic oncology: forword. *Onkologie.* 2013;36 Suppl 6:1. German. No abstract available.
  62. Overbeck T, Schäper C, **Griesinger F**, Gröschel A, Haug A, Leschber G, Pfluger T, Pöttgen C. Tumor Conference I. *Onkologie.* 2013;36 Suppl 6:2-4. doi: 10.1159/000353714. Epub 2013 Aug 12. German. No abstract available.
  63. Tabriz N, Tannapfel A, **Griesinger F**, Weyhe D. Chloroma of pancreas-initial manifestation of a secondary leukemia after stem cell transplantation case report and review of the literature. *J Gastrointest Surg.* 2013 Jul;17(7):1331-5. doi: 10.1007/s11605-013-2166-9. Epub 2013 Feb 16.
  64. Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, **Griesinger F**, Thomas M; TREAT investigators. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. *Ann Oncol.* 2013 Apr;24(4):986-92. doi: 10.1093/annonc/mds578. Epub 2012 Nov 15.

65. Nitsche M, Christiansen H, Lederer K, **Griesinger F**, Schmidberger H, Pradier O. Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study. *J Cancer Res Clin Oncol*. 2012 Jul;138(7):1113-20. doi: 10.1007/s00432-012-1185-3. Epub 2012 Mar
66. Dansin E, Cinieri S, Garrido P, **Griesinger F**, Isla D, Koehler M, Kohlhäufel M. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. *Lung Cancer*. 2012 Jun;76(3):373-9. doi: 10.1016/j.lungcan.2011.11.020. Epub 2012 Jan 10.
67. **Griesinger F**, Huber RM, Thomas M, Wolf M. [Thoracic oncology - optimization through integrated approaches, quality assurance, and molecular biology. Forward]. *Onkologie*. 2012;35 Suppl 3:1. doi: 10.1159/000338991. Epub 2012 May 15. German. No abstract available.
68. Eberhardt W, **Griesinger F**, Filipits M, Winter H. [Early staging in non-small cell lung cancer]. *Onkologie*. 2012;35 Suppl 3:6-9. doi: 10.1159/000338977. Epub 2012 May 15. German. No abstract available.
69. Gridelli C, Bennouna J, de Castro J, Dingemans AM, **Griesinger F**, Grossi F, Rossi A, Thatcher N, Wong EK, Langer C. Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial. *Clin Lung Cancer*. 2011 Jun 24. [Epub ahead of print]
70. Fischer JR, **Griesinger F**, Fink T, Salm T, Marseille A, Wolf M. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)-Results of the nonrandomised phase II study TaxErb. *Lung Cancer*. 2011 Sep 9. [Epub ahead of print] Impact
71. Overbeck TR, **Griesinger F**. Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy?. *Dermatology*. 2012;225(2):179-82. doi: 10.1159/000342786. Epub 2012 Oct 20. Review
72. T. Rippberger, M. Tauscher, D. Haase, **F. Griesinger**, B. Schlegelberger, and D. Steinemann Managing individuals with propensity to myeloid malignancies due to germline RUNX1 deficiency.. 2011, *Haematologica* Aug 31, epub Impact
73. Gridelli C, Bennouna J, de Castro J, Dingemans AM, **Griesinger F** et al. Randomized Phase IIIb trial evaluation the continuation of bevacizumab beyond disease progression in patients with advance non – squamous non-small cell lung cancer after first line treatment with bevacizumab plus platinum base chemotherapy: treatment rationale and protocol dynamics of the Ava ALL (MO22097) trial: *Clinical Lung Cancer* 2011;12;407-411.
74. Hohloch K, Lakhani VJ, Sahlmann C, Wulf G, Meller J, Trümper L, **Griesinger F**. Tandem-high dose therapy in relapsed and refractory B-cell lymphoma, Phase II trial of a myeloablative chemotherapy followed by escalated radioimmunotherapy with I131 anti CD20 antibody. *Ann. Hematol* 2011 Nov;90(11):1307-15. doi: 10.1007/s00277-011-1199-y. Epub 2011 Mar 1.
75. Jahnke K, Martus P, Lokka S, .. Griesinger F. et al., Prognostic factors and score for response and survival in primary central nervous system lymphoma from a randomized phase III trial. *Onkologie* 2011;34;296.
76. Meyer F, **Griesinger F**, Willborn K, Sambale R, Thomé C. Treatment strategies for the multidisciplinary management of spinal metastasis]. *Dtsch Med Wochenschr*. 2011 Sep;136(38):1907-12. Epub 2011 Sep 13. German.
77. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, **Griesinger F**, Niederle N, Stuschke M, Blum T, Deppermann KM, Ficker JH, Freitag L, Lübke AS, Reinhold T, Späth-Schwalbe E, Ukena D, Wickert M, Wolf M, Andreas S, Auberger T, Baum RP, Baysal B, Beuth J, Bickeböller H, Böcking A, Bohle RM, Brüske I, Burghuber O, Dickgreber N, Diederich S, Dienemann H, Eberhardt W, Eggeling S, Fink T, Fischer B, Franke M, Friedel G, Gauler T, Gütz S, Hautmann H, Hellmann A, Hellwig D, Herth F, Heußel CP, Hilbe W, Hoffmeyer F, Horneber M, Huber RM, Hübner J, Kauczor HU, Kirchbacher K, Kirsten D, Kraus T, Lang SM, Martens U, Mohn-Staudner A, Müller KM, Müller-Nordhorn J, Nowak D, Ochmann U, Passlick B, Petersen I, Pirker R, Pokrajac B, Reck M, Riha S, Rube C, Schmittel A, Schönfeld N, Schütte W, Serke M, Stamatis G, Steingraber M, Steins M, Stoelben E, Swoboda L, Teschler H, Tessen HW, Weber M, Werner A, Wichmann HE, Irlinger Wimmer E, Witt C, Worth H. Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer. *Pneumologie*. 2011 Aug;65(8):e51-e75. Epub 2011 Aug 9. German. No abstract available.
78. **Griesinger F**, Huber RM, Thomas M. *Onkologie*. 2011;34 Suppl 4:1. Epub 2011 May 13. German. No abstract available

79. A Stenger I, Tomala C, Pietsch M, Olgemoeller U, Koerber W, Fischer B, Sebastian M, Truemper L, Overbeck T, **Griesinger F**. Mitomycin C in combination with vinorelbine or cisplatin and erythropoietin in pretreated patients with in field relapse after radiation therapy of non-small cell lung cancer: a phase II trial of the AIO. MEMO 2011
80. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, **Griesinger F**, Niederle N, Stuschke M, Blum T, Deppermann KM, Ficker JH, Freitag L, Lübke AS, Reinhold T, Späth-Schwalbe E, Ukena D, Wickert M, Wolf M, Andreas S, Auberger T, Baum RP, Baysal B, Beuth J, Bickeböller H, Böcking A, Bohle RM, Brüske I, Burghuber O, Dickgreber N, Diederich S, Dienemann H, Eberhardt W, Eggeling S, Fink T, Fischer B, Franke M, Friedel G, Gauler T, Gütz S, Hautmann H, Hellmann A, Hellwig D, Herth F, Heußel CP, Hilbe W, Hoffmeyer F, Horneber M, Huber RM, Hübner J, Kauczor HU, Kirchbacher K, Kirsten D, Kraus T, Lang SM, Martens U, Mohn-Staudner A, Müller KM, Müller-Nordhorn J, Nowak D, Ochmann U, Passlick B, Petersen I, Pirker R, Pokrajac B, Reck M, Riha S, Rube C, Schmittel A, Schönfeld N, Schütte W, Serke M, Stamatis G, Steingraber M, Steins M, Stoelben E, Swoboda L, Teschler H, Tessen HW, Weber M, Werner A, Wichmann HE, Irlinger Wimmer E, Witt C, Worth H. Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer. *Pneumologie*. 2011 65(8):39-59. German. No abstract available. Impact
81. Thiel E, Korfel A, Martus P, Kanz L, **Griesinger F**, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. *Lancet Oncol*. 2010 Nov;11(11):1036-47. Epub 2010 Oct 20.
82. Crinò L, Dansin E, Garrido P, **Griesinger F**, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. *Lancet Oncol*. 2010 Aug;11(8):733-40. Epub 2010 Jul 23
83. Gatzemeier U, **Griesinger F**, Huber RM, Thomas M. A Paradigm Shift in Local and Systemic treatment of NSCLC ? *Onkologie* 2010;33;1.
84. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, **Griesinger F**, Niederle N, Stuschke M, Blum T, Deppermann KM, Ficker JH, Freitag L, Lübke AS, Reinhold T, Späth-Schwalbe E, Ukena D, Wickert M, Wolf M, Andreas S, Auberger T, Baum RP, Baysal B, Beuth J, Bickeböller H, Böcking A, Bohle RM, Brüske I, Burghuber O, Dickgreber N, Diederich S, Dienemann H, Eberhardt W, Eggeling S, Fink T, Fischer B, Franke M, Friedel G, Gauler T, Gütz S, Hautmann H, Hellmann A, Hellwig D, Herth F, Heußel CP, Hilbe W, Hoffmeyer F, Horneber M, Huber RM, Hübner J, Kauczor HU, Kirchbacher K, Kirsten D, Kraus T, Lang SM, Martens U, Mohn-Staudner A, Müller KM, Müller-Nordhorn J, Nowak D, Ochmann U, Passlick B, Petersen I, Pirker R, Pokrajac B, Reck M, Riha S, Rube C, Schmittel A, Schönfeld N, Schütte W, Serke M, Stamatis G, Steingraber M, Steins M, Stoelben E, Swoboda L, Teschler H, Tessen HW, Weber M, Werner A, Wichmann HE, Irlinger Wimmer E, Witt C, Worth H. Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer. *Pneumologie*. 2010;64 Suppl 2:31-164.
85. Agarwal JR, **Griesinger F**, Stühmer W, Pardo LA. The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. *Mol Cancer*. 2010 Jan 27;9:18.
86. Gatzemeier U, **Griesinger F**, Huber R, Thomas M. Preface. *Onkologie* 2009; 32:1 Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
87. Gatzemeier U, **Griesinger F**, Huber RM, Thomas M. *Onkologie*. 2008;31 Suppl 3:V. German.
88. Baesecke J, Podleschny M, Becker A, Seiffert E, Schwiers I, Schwiers R, Haase D, Glass B, Schmitz N, Trumper L, **Griesinger F**. Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma. *Br J Haematol*. 2008 Apr;141(1):52-9.
89. Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B, Rosenbauer F, Becker A, Wagner K, Koschmieder S, Kobayashi S, Costa DB, Schulz T, O'Brien KB, Verhaak RG, Delwel R, Haase D, Trümper L, Krauter J, Kohwi-Shigematsu T, **Griesinger F**, Tenen DG. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. *J Clin Invest*. 2007 Sep;117(9):2611-20.
90. Gralla RJ, **Griesinger F**. Interpreting clinical trials in lung cancer: impact of methodology and endpoints. *J Thorac Oncol*. 2007 Jun;2 Suppl 2:S51-8. Review.
91. Kreuter M, Vansteenkiste J, **Griesinger F**, Hoffmann H, Dienemann H, De Leyn P, Thomas M. Trial on refinement of early stage non-small cell lung cancer. Adjuvant

- chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. *BMC Cancer*. 2007 May 8;7:77.
92. Hallermann C, Kaune KM, Tiemann M, Kunze E, **Griesinger F**, Mitteldorf C, Bertsch HP, Neumann C. High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. *Ann Hematol*. 2007 Jul;86(7):509-15. Epub 2007 Mar 6. Erratum in: *Ann Hematol*. 2007 Jul;86(7):517. Kaune, Matthias Kjell [corrected to Kaune, Kjell Matthias].
  93. Chapuy B, Wulf G, Tessen HW, **Griesinger F**, Trümper L, Schroers R. [Asymptomatic 32 year old female smoker with persistent polyclonal lymphocytosis] *Internist (Berl)*. 2007 Mar;48(3):314-8. German.
  94. Eberhardt W, Fietkau R, **Griesinger F**, Passlick B, Stuschke M. [Surgery and adjuvant therapy in non-small-cell lung carcinoma (NSCLC). (stage I through operable stage IIIA)] *Onkologie*. 2006 Sep;29 Suppl 2:7-10. Epub 2006 Sep 6. Review. German.
  95. Gatzemeier U, **Griesinger F**, Huber RM. [Pillnitz interdisciplinary discussion--summary] *Onkologie*. 2006 Sep;29 Suppl 2:2. Epub 2006 Sep 6. German.
  96. Basecke J, Whelan JT, **Griesinger F**, Bertrand FE. The MLL partial tandem duplication in acute myeloid leukaemia. *Br J Haematol*. 2006 Nov;135(4):438-49. Epub 2006 Sep 11. Review.
  97. MRD-AML-BFM Study Group, Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, **Griesinger F**, Zimmermann M, Reinhardt D. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. *J Clin Oncol*. 2006 Aug 1;24(22):3686-92.
  98. Basecke J, Karim K, Podleschny M, Becker A, Glass B, Trumper L, **Griesinger F**. MLL rearrangements emerge during spontaneous apoptosis of clinical blood samples. *Leukemia*. 2006 Jun;20(6):1193-4.
  99. Bäsecke J, Podleschny M, Clemens R, Schnittger S, Viereck V, Trümper L, **Griesinger F**. Lifelong persistence of AML associated MLL partial tandem duplications (MLL-PTD) in healthy adults. *Leuk Res*. 2006 Sep;30(9):1091-6. Epub 2006 Mar 15
  100. Meyer C, Schneider B, Jakob S, Strehl S, Attarbaschi A, Schnittger S, Schoch C, Jansen MW, van Dongen JJ, den Boer ML, Pieters R, Ennas MG, Angelucci E, Koehl U, Greil J, **Griesinger F**, Zur Stadt U, Eckert C, Szczepański T, Niggli FK, Schäfer BW, Kempfski H, Brady HJ, Zuna J, Trka J, Nigro LL, Biondi A, Delabesse E, Macintyre E, Stanulla M, Schrappe M, Haas OA, Burmeister T, Dingermann T, Klingebiel T, Marschalek R. The MLL recombinome of acute leukemias. *Leukemia*. 2006 May;20(5):777-84
  101. **Griesinger F**, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, Wormann B, Haase D, Bohlander SK. (2005) A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. *Genes Chromosomes Cancer*. 44:329-33.
  102. Basecke J, Schwieger M, **Griesinger F**, Schiedlmeier B, Wulf G, Trumper L, Stocking C. (2005) AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation. *Leuk Lymphoma* 46:265-272.
  103. Schroers R, Hildebrandt Y, Steffens R, Becker S, Ohms G, von Bonin F, Haase D, Bertsch HP, Trumper L, **Griesinger F**. (2005). Immunophenotypic and genetic characterization of a CD8 positive mantle cell lymphoma in a patient with concomitant Mycosis fungoides. *Eur J Haematol*. Jul;75(1):78-84.
  104. Schroers R, **Griesinger F**, Trumper L, Haase D, Kulle B, Klein-Hitpass L, Sellmann L, Duhrsen U, Durig J. (2005) Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. *Leukemia*. 19:750-8.

105. Langebrake C, Brinkmann I, Teigler-Schlegel A, Creutzig U, **Griesinger F**, Puhlmann U, Reinhardt D. (2005) Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. *Cytometry B Clin Cytom.* 63:1-9.
106. Wulf GG, Modlich S, Inagaki N, Reinhardt D, Schroers R, **Griesinger F**, Trumper L (2004). ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. *Haematologica.* 89:1395-1397.
107. Hallermann C, Middel P, **Griesinger F**, Gunawan B, Bertsch HP, Neumann C (2004). CD4+ CD56+ blastic tumor of the skin: cytogenetic observations and further evidence of an origin from plasmacytoid dendritic cells. *Eur J Dermatol* 14:317-322.
108. Hallermann C, Kaune K M, Gesk S, Martin-Subero J I, Gunawan B, **Griesinger F**, Vermeer MH, Santucci M, Pimpinelli N, Willemze R, Siebert R, Neumann C (2004). Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. *J Invest Dermatol* 123:213-219.
109. Schroers R, Pukrop T, Durig J, Haase D., Duhrsen, U., Trumper, L., **Griesinger, F.** (2004) B-cell chronic lymphocytic leukemia with aberrant CD8 expression: genetic and immunophenotypic analysis of prognostic factors. *Leuk Lymphoma* 45:1677-1681.
110. **Griesinger F**, Metz M, Trumper L, Schulz T, Haase D (2004). Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB. *Lung Cancer* 44:261-265.
111. Schlenk, R. F., Frohling, S., Hartmann, F., Fischer, J. T., Glasmacher, A., del Valle, F., Griminger, W., Gotze, K., Waterhouse, C., Schoch, R., Pralle, H., Mergenthaler, H. G., Hensel, M., Koller, E., Kirchen, H., Preiss, J., Salwender, H., Biedermann, H. G., Kremers, S., **Griesinger, F.**, Benner, A., Addamo, B., Dohner, K., Haas, R., Dohner, H. (2004) Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. *Leukemia* 18: 1798-1803
112. Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, Podleschny M, Hahlen K, Pieters R, Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJ, **Griesinger F** (2003): FLT3 internal tandem duplication in 234 children with acute myeloid leukemia (AML): prognostic significance and relation to cellular drug resistance. *Blood.* 102:2387-2394
113. Wassmann B, Scheuring U, Thiede C, Pfeifer H, Bornhäuser M, **Griesinger F**, Hochhaus A, Schleyer E, Gschaidmeier H, Hoelzer D, Ottmann, OG. (2003) Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. *Bone Marrow Transpl* 31:611-614
114. Schmücking M, Baum, RP, **Griesinger F**, Presselt N, Bonnet R, Przetak C, Niesen A, Leonhardi J, Lopatta EC, Herse B, Wendt TG (2003) Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. *Recent Results Cancer Res.* 162:195-202
115. **Griesinger F**, Oberbeck T, Trümper L (2003) Neue Therapieansätze beim Bronchialkarzinom. *Zeitschrift für Allgemeinmedizin*, 79: 90-97
116. Grundker C, Volker, P, **Griesinger F**, Ramaswamy A, Nagy A, Schally AV, Emons G (2002). Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. *Am J Obstet Gynecol* 187:528-537.
117. Reinhardt D, Langebrake C, Creutzig U, Vormoor J, Brune C, Thorwesten M, Ingiliz P, Hrusak O, Dworzak M, **Griesinger F.** (2002) Minimal residual disease in

- acute myeloid leukemia in children - standardization and evaluation of immunophenotyping in the AML-BFM-98 study, *Klin Padiatr* 214:179-187
118. Basecke J, **Griesinger F**, Trümper L, Brittinger G. (2002) Leukemia- and lymphoma-associated genetic aberrations in healthy individuals. *Ann Hematol* 81:64-75
  119. Basecke J, Feuring-Buske M, Brittinger G, Schaefer UW, Hiddemann W, **Griesinger F**. (2002) Transcription of AML1 in hematopoietic subfractions of normal adults. *Ann Hematol* 81:254-257
  120. Baesecke J, Cepek L, Mannhalter C, Krauter J, Hildenhagen S, Brittinger G, Truemper L, **Griesinger F**. (2002) Transcription of AML1-ETO in bone marrow and cord blood of individuals without AML. *Blood* 100: 2267-2268
  121. **Griesinger F**, Janke A, Podleschny, M, Bohlander S (2002). Identification of an ETV6-ARG fusion transcript in combination with an ETV6 point mutation in a multipotent ALL cell line. *Br J Hematol* *Br J Haematol*. 119:454-458.
  122. Behr, TM, Liersch T, Greiner-Bechert L, **Griesinger F**, Béhé M, Markus PM, Gratz S, Angerstein C, Brittinger G, Becker H, Goldenberg DM, Becker W. (2002) Radioimmunotherapy of small volume disease of metastatic colorectal cancer. *Cancer* 94:1373-1381
  123. Fasching K, Panzer S, Haas OA, Borkhardt A, Marschalek R, **Griesinger F**, Panzer-Grümayer R (2001) The presence of N regions in the clonotypic DJ rearrangements of the Ig heavy chain genes indicate an exquisitely short latency in t(4;11) positive infant acute lymphoblastic leukemia. *Blood* 98:2272-2274
  124. Haase D, Schulz T, Binder C, Fonatsch C, Schnittger S, **Griesinger F**, Westphal G, Bünger J, Schoch C, Wörmann B, Hallier E. (2002) Increased risk for therapy-induced hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene defects of glutathione transferases M1 and T1. *Leuk Res*. 26:249-254.
  125. Buchner T, Hiddemann W, Wormann B, Löffler H, Ludwig WD, Schoch C, Haferlach T, Maschmeyer G, Staib P, Aul C, Heyll GA, Gruneisen A, Rasche H, Eimermacher JH, Balleisen L, Pielken HJ, Reis HE, **Griesinger F**, Reichle A, Sauerland MC, Heinecke A. (2000) Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary? German AMLCG. *Int J Hematol*; 72:285-289
  126. Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T, Büchner T, Wörmann B, Hiddemann W, **Griesinger F**. (2000) MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of karyotypically normal AML. *Leukemia* 2000; 14:796-804
  127. **Griesinger F**, Pirò-Noack M, Falk M, Kaib N, Troff C, Grove D, Büchner T, Ritter J, Hiddemann W, Wörmann B (1999) Leukemia-associated immunophenotypes by 3-color flow cytometry are observed in 90% of childhood and adult acute lymphoblastic leukemia at diagnosis and predict clinical outcome in remission marrow. *Br. J. Hematol*. 105: 241-255
  128. Gillert E, Leis T, Repp R, Reichel M, Hösch A, Breitenlohner I, Angermüller S, Borkhardt A, Harbott J, Lampert F, **Griesinger F**, Greil J, Fey, G, Marschalek R. (1999) A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells. *Oncogene* 18:4663-4671
  129. van Dongen JJM, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio E, Gottardi E, Rambaldi A, Dotti G, **Griesinger F**, Parreira A, Gameiro P, Gonzalez Diaz M, Malec M, Langerak AW, San Miguel JF, Biondi A. (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. *Leukemia* 13:1901-1928

130. Peters AM, Kohlfink D, Martin H, **Griesinger F**, Wörmann B, Gahr M, Roesler J (1999) Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma and Hodgkin's disease. *Exp Hematol* 27:868-874
131. Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Behe M, **Griesinger F**, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W. (1999) Low vs high dose radioimmunotherapy with humanized anti-CD22 or chimeric anti CD20 antibodies in a broad spectrum of B-cell associated malignancies. *Clin Cancer Res.* 5: 3304S-3314S
132. Schnittger S, Wörmann B, Hiddemann W, **Griesinger F**. (1998) Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. *Blood* 92: 1728-1734
133. Herse B, Dalichau H, Wörmann B, Hemmerlein B, Schmidberger H, Hess CF, Hannemann P, Criege CP, Hiddemann W, **Griesinger F**. (1998) Outpatient induction chemotherapy with docetaxel/carboplatin in advanced non-small-cell lung cancer (NSCLC). *Thorac Cardiovasc Surg* 46:298-302
134. Buske C, Becker D, Feuring-Buske M, Hannig H, **Griesinger F**, Schneider E-M, Hiddemann W, Woermann B. (1998) TGF beta and its complex in leukemic B-cell precursors. *Exp Hematol* 26:1155-1161
135. **Griesinger F**, Elfers H, Ludwig W-D, Falk M, Rieder H, Harbott J, Lampert F, Heinze B, Hoelzer D, Thiel E, Riehm H, Wörmann B, Fonatsch C, Hiddemann W. (1994) Detection of HRX-FEL fusion transcripts in pre-pre-B-ALL with and without cytogenetic demonstration of t(4;11). *Leukemia*; 8:542-548.
136. **Griesinger F**, Grümayer ER, Van Ness B, Kersey JH. (1992) Rearrangement and diversification of T cell receptor delta genes in acute lymphoblastic leukemia. *Leukemia*, 6:1054-1062.
137. **Griesinger F**, Jansen B, Kersey JH (1991). Differentiation in mature T lymphoid leukemia cells is unstable and reversible to myeloid cells, without the involvement of a common stem cell. *J Immunol*, 147:333-341.
138. **Griesinger F**, Younger PW, Kersey JH. (1991) Organization of the T-cell receptor alpha/delta locus by deletional analysis of acute lymphoblastic leukemias and leukemic cell lines. *Leukemia*, 5: 673-679.
139. Grümayer ER, **Griesinger F**, Hummel DS, Brunning RD, Kersey JH. (1991) Identification of novel B-lineage cells in human fetal bone marrow which coexpress CD7. *Blood*, 77: 64-68.
140. **Griesinger F**, Bergmann L, Barot-Ciorbaru R, Mitrou PS. (1990) Intrinsic B-lymphocyte defect in patients with untreated Hodgkin's disease. *Clin Immunol Immunother*, 32:256-260.
141. LeBien TW, Elstrom RL, Kersey JH, **Griesinger F**. (1990) Analysis of immunoglobulin and T-cell-receptor gene rearrangements in human fetal bone marrow B lineage cells. *Blood*, 76:1196-1200.
142. **Griesinger F**, Arthur DC, Brunning R, Parkin JL, Ochoa AC, Miller WJ, Greenberg JM, Hurvitz C, Kersey JH. (1989) Mature T-lineage leukemia with growth factor induced multi-lineage differentiation. *J. Exp. Med.* 169:1101-1120.
143. **Griesinger F**, Greenberg JM, Kersey JH. (1989) T-cell receptor gamma and delta rearrangements in hematological malignancies: relationship to lymphoid differentiation. *J. Clin. Invest.* 84: 506-516.
144. Ganser A, Carlo-Stella C, Bartram CR, Böhm T, Heil G, Henglein B, Müller H, Raghavachar AN., von Briesen H, **Griesinger F**, Völkers B, Rübsamen-Waigman H, Helm EB, Hoelzer D. (1988) Establishment of two Epstein-Barr virus negative Burkitt cell lines from a patient with AIDS and B-cell lymphoma. *Blood* 73:31.

### Reviews:

1. Griesinger F. Systemtherapie bei molekularen Subgruppen des nicht-kleinzelligen Lungenkarzinoms. Trillium Krebs und Medizin 2014)
2. Griesinger F. Klinische Studien in der Ära der molekular stratifizierten Therapie, Forum Onkologie 2014
3. Griesinger F. Review Artikel Butts et al. Lancet Oncology 2014. Focus Oncology 2014.
4. Griesinger F: Aktuelle Systemtherapie des metastasierten Lungenkarzinoms Journal Onkologie 9/12

### Books:

1. Griesinger F: Nausea und Emesis in der Onkologie:Kapitel Nausea und Emesis bei Lungenkarzinomen. Unimed Verlag, Ed. F. Lordick, 2016
2. Griesinger F: Nausea und Emesis in der Onkologie:Kapitel Nausea und Emesis bei Lungenkarzinomen. Unimed Verlag, Ed. F. Lordick, 2014
3. **Griesinger F.** Biology and Detection of t(4;11) ALL. in Haematology and Blood Transfusion: Acute Leukemias VI. Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J, Creutzig W (Eds.), 1997, pp82-89
4. **Griesinger F,** Kaib, N, Könemann S, Maecker B, Prio-Noack M, Falk M, Ritter J, Büchner T, Hiddemann W, Terstappen LWMM, Wörmann B. Characterization of normal and leukemia lymphohematopoietic precursor cells (LHPC) by three-color-flow-cytometry and detection of clone-specific leukemia-associated T-cell-receptor d rearrangements.in Haematology and Blood Transfusion: Acute Leukemias VI. Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J, Creutzig W (Eds.), 1997, pp224-231
5. **Griesinger F,** Jahn T, Elfers H, Ludwig W-D, Falk M, Rieder H, Harbott J, Lampert F, Heinze B, Hoelzer D, Thiel E, Riehm H, Wörmann B, Fonatsch C, Hiddemann W. Heterogeneity of HRX-FEL fusion transcripts in adult and pediatric t(4;11) ALL.in Haematology and Blood Transfusion: Acute Leukemias V, Hiddemann W, Büchner T, Wörmann B, Ritter J, Creutzig U, Keating MJ, Plunkett W (Eds), 1996, pp. 15-24.
6. Wörmann B, Grove D, Falk M, Könemann, S., Markloff Y, Toepker S, Heyll A, Aul C, Ritter J, Büchner T, Hiddemann W, Terstappen LWMM, **Griesinger F.** Distrubution of cells with a „stem cell like“ immunophenotype in acute leukemia. in Haematology and Blood Transfusion: Acute Leukemias V, Hiddemann W, Büchner T, Wörmann B, Ritter J, Creutzig U, Keating MJ, Plunkett W (Eds), 1996, pp. 506-513.

### Media publicity:



1. Frank Griesinger, Europäischer Krebskongress - Lungenkrebs: Die Therapiepraxis verändernde Studien (<https://www.krebsgesellschaft.de/onko-internetportal/kongresse/esmo/lungenkrebstherapie-bei-alk-oder-egfr-mutation.html>)
2. Frank Griesinger, Markus Tiemann, Niels Reinmuth – Der NSCLC-Therapeut zwischen Studien, Leitlinien und seinem Patienten (<https://eacademy.sanofi.de/mediathek/110>)
3. Frank Griesinger – Springer Medizin Im Focus Onkologie: CRISP-Register: Test- und Therapierealität bei Lungenkrebs